

Resource Summary Report

Generated by [dkNET](#) on Aug 31, 2026

CHP-134

RRID:CVCL_1124

Type: Cell Line

Proper Citation

ECACC Cat# 06122002, RRID:CVCL_1124

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1124

Proper Citation: ECACC Cat# 06122002, RRID:CVCL_1124

Description: Cell line CHP-134 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adrenal gland neuroblastoma

Defining Citation: [PMID:10079](#), [PMID:71759](#), [PMID:6113887](#), [PMID:6888561](#), [PMID:7139592](#), [PMID:12702577](#), [PMID:15892104](#), [PMID:16822308](#), [PMID:18724359](#), [PMID:18923524](#), [PMID:20164919](#), [PMID:22213050](#), [PMID:23202128](#), [PMID:24466371](#), [PMID:27397505](#), [PMID:28350380](#), [PMID:30894373](#)

Comments: Karyotypic information: Pseudodiploid (PubMed=71759)., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: CHP-134

Synonyms: CHP 134, CHP_134, CHP134, Children's Hospital of Philadelphia-134

Cross References: BTO:BTO_0002989, CLO:CLO_0051417, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, BioSample:SAMN03472330, BioSample:SAMN03473466, cancercellines:CVCL_1124, Cell_Model_Passport:SIDM00285, CGH-DB:75-1, CGH-DB:9099-4, ChEMBL-Cells:ChEMBL3308253, ChEMBL-Targets:ChEMBL2366128, Cosmic:688063, Cosmic:801744, Cosmic:848934, Cosmic:910941, Cosmic:920253, Cosmic:930063,

Cosmic:947707, Cosmic:1019934, Cosmic:1037353, Cosmic:1099150, Cosmic:1109362, Cosmic:1153779, Cosmic:1161986, Cosmic:1526620, Cosmic:2131592, Cosmic:2393629, Cosmic:2485943, Cosmic-CLP:910941, DepMap:ACH-001338, DSMZ:ACC-653, DSMZCellDive:ACC-653, ECACC:06122002, EGA:EGAS00001000978, FANTOM5_SSTAR:10508-107D4, GDSC:910941, GEO:GSM313800, GEO:GSM333795, GEO:GSM563356, GEO:GSM692863, GEO:GSM1366404, GEO:GSM1669677, GEO:GSM2371222, GEO:GSM2394376, GEO:GSM3145587, GEO:GSM3145699, IARC_TP53:21226, PharmacDB:CHP134_199_2019, Progenetix:CVCL_1124, PubChem_Cell_line:CVCL_1124, RCB:RCB0487, Wikidata:Q54813265

ID: CVCL_1124

Vendor: ECACC

Catalog Number: 06122002

Record Creation Time: 20220427T215505+0000

Record Last Update: 20260829T231838+0000

Ratings and Alerts

No rating or validation information has been found for CHP-134.

No alerts have been found for CHP-134.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Pommerenke C, et al. (2026) Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling. iScience, 29(7), 116469.

Ludwig M, et al. (2026) YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells. Cancers, 18(3).

Li S, et al. (2025) Small molecule UCM05 inhibits HSV-2 infection via targeting viral glycoproteins and fatty acid synthase with potentiating antiviral immunity. Virology journal, 22(1), 249.

Montuori G, et al. (2025) Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. Cancer discovery, 15(10), 2054.

Za?uska-Ogryzek K, et al. (2025) Isobolographic interactions of cannabidiol and AM 1172 with cisplatin in human neuroblastoma and glioblastoma cell lines: An in vitro study. *Chemico-biological interactions*, 408, 111392.

Volegova MP, et al. (2024) The MYCN 5' UTR as a therapeutic target in neuroblastoma. *Cell reports*, 43(5), 114134.

Bate-Eya LT, et al. (2024) Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma. *Molecular oncology*.

Rösch L, et al. (2023) ERBB and P-glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P-glycoprotein. *Molecular oncology*, 17(1), 37.

Jiang H, et al. (2023) Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. *Cancer research*, 83(2), 181.

Yang Y, et al. (2023) Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity. *Cellular oncology (Dordrecht)*, 46(1), 133.

Dong Z, et al. (2021) GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma. *Cancer research*, 81(11), 2995.

Guarnaccia AD, et al. (2021) Impact of WIN site inhibitor on the WDR5 interactome. *Cell reports*, 34(3), 108636.

Dirks WG, et al. (2021) Cross contamination meets misclassification: Awakening of CHP-100 from sleeping beauty sleep-A reviewed model for Ewing's sarcoma. *International journal of cancer*.

Arlt B, et al. (2021) Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma. *International journal of cancer*, 148(5), 1219.

Chen J, et al. (2021) Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(5), 1438.

Buongervino S, et al. (2021) Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization. *Molecular cancer therapeutics*, 20(11), 2228.

Batth IS, et al. (2020) Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients. *International journal of cancer*, 147(12), 3550.

Saito EY, et al. (2020) Sindbis viral structural protein cytotoxicity on human neuroblastoma cells. *Pediatric surgery international*, 36(10), 1173.

Tee AE, et al. (2020) Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma. *International journal of cancer*, 147(7), 1928.

Hsu JH, et al. (2020) EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex. *Cell chemical biology*, 27(1), 41.